Form 4: Cytosorbents Director Edward Jones Boosts Stake

Cytosorbents Director Edward R. Jones acquired 22,000 stock options and holds 88,834 common shares and RSUs, as detailed in a recent SEC filing.

Summary

• Director Edward R. Jones reported beneficial ownership of 88,834 shares of Cytosorbents Corp common stock.
• This total includes 69,300 Restricted Stock Units (RSUs) granted between April 8, 2015, and March 15, 2018, which are set to vest upon a 'Change In Control' of the Company.
• The remaining 19,534 shares are directly owned common stock.
• On August 8, 2025, Mr. Jones acquired 22,000 stock options with an exercise price of $1 per share.
• These stock options will vest in four equal quarterly installments over one year following the grant date and are set to expire on August 8, 2035.
• Mr. Jones also granted a Limited Power of Attorney to Peter J. Mariani, the Chief Financial Officer, effective August 8, 2025, to handle his Section 16(a) reporting obligations.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director signals continued alignment of interests with shareholders and confidence in future company performance.

Positives

• Director Edward R. Jones acquired 22,000 stock options, signaling continued commitment and potential confidence in the company's future performance.
• The director maintains a significant beneficial ownership stake of 88,834 common shares and RSUs, aligning his interests with shareholders.

Future Outlook

The vesting schedule for the acquired stock options and existing Restricted Stock Units implies a continued service commitment from the director, aligning with future company performance.

Industry Context

This filing details an individual insider transaction, which is specific to the reporting person's equity holdings and compensation, rather than providing broader industry trends or competitive analysis.

Corporate Governance

Stakeholder Impact

• Shareholders may view the director's increased equity stake as a positive sign of management's commitment and belief in the company's long-term prospects.

Next Steps

• Vesting of 22,000 stock options in four equal quarterly installments over one year following the August 8, 2025 grant date.
• Vesting of 69,300 Restricted Stock Units upon a 'Change In Control' of the Company.

Key Dates

Recommendation

The acquisition of new stock options by a director, coupled with existing significant equity holdings, is a positive indicator of management's belief in the company's long-term prospects and aligns their interests with shareholders. However, this Form 4 primarily details insider compensation and ownership, and does not provide broader financial or strategic updates to warrant a change from a 'hold' position without further comprehensive analysis.

Keywords

Cytosorbents, CTSO, Edward Jones, Director, Stock Option, RSU, Insider Trading, SEC Form 4, Equity Compensation